Resultados de la búsqueda 181-190 of 14508 for Severe hypokalaemia

1. Mayo Clinic Digestive Diseases Physician Update - October 2025

   Page 1.

2. Nefrología e hipertensión - Ensayos clínicos - Mayo Clinic

   A standard treatment is considered not well tolerated if the patient experiences severe side effects without providing an acceptable level of clinical benefit.

3. Hematología - Ensayos clínicos - Mayo Clinic

   All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...

4. Hematología - Ensayos clínicos - Mayo Clinic

   This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...

5. Médicos y departamentos

   FDA approves first medication to treat severe frostbite (news release). U.S. Food and Drug Administration. https://www.fda.gov. Accessed Feb. 14, 2024 ...

6. Hematología - Ensayos clínicos - Mayo Clinic

   This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...

7. Mayo Clinic Digestive Diseases Physician Update e-Edition, June 2015

   Bile acid malabsorption (BAM)) occurs in about 1 in 3 patients with IBS-D and up to 50 percent of those with functional diarrhea, yet it remains underdiagnosed.

8. Ensayos clínicos - Hematología

   This clinical trial studies the effect of short-term (acute) and long-term (chronic) exercise on immune characteristics and function (phenotype) of patients ...

9. Mayo Clinic Digestive Diseases Physician Update - July 2025

   Page 1.

10. Hematología - Ensayos clínicos - Mayo Clinic

    All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...